Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Transurethral Surgery Followed by a Combination of Atezolizumab (Tecentriq) an Anti-PDL-1 (MPDL3280A) With Trimodal Therapy in Patients With Muscle-Invasive Bladder Cancer

Next Previous
Trial Profile

A Phase II Trial of Transurethral Surgery Followed by a Combination of Atezolizumab (Tecentriq) an Anti-PDL-1 (MPDL3280A) With Trimodal Therapy in Patients With Muscle-Invasive Bladder Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Gemcitabine (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions

Most Recent Events

  • 18 May 2020 Status changed from recruiting to discontinued.as per results presented at the 115th Annual Meeting of the American Urological Association
  • 18 May 2020 Results (N=8, between December 2017 and January 2019) presented at the 115th Annual Meeting of the American Urological Association
  • 17 Aug 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top